Sign In
Buy HCM
$9.99
-0.290 (-2.82%)
At Close: Jun 22, 2026
Homeland Provides Clarification on Prior Investor Relations Services Agreement with HoldCo Markets
04:00am, Thursday, 15'th Jan 2026
Vancouver, British Columbia--(Newsfile Corp. - January 15, 2026) - Homeland Uranium Corp. (TSXV: HLU) (OTCQB: HLUCF) (FSE: D3U) ("Homeland" or the "Company"), at the request of the TSX Venture Exchang
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
11:00pm, Tuesday, 13'th Jan 2026
— First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after progression on prior EGFR-TKI treatment —
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--BMS Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos in Adolescents with Symptomatic oHCM.
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Given Average Recommendation of “Hold” by Analysts
05:24am, Sunday, 11'th Jan 2026
HUTCHMED (China) Limited Sponsored ADR (NASDAQ: HCM - Get Free Report) has received a consensus recommendation of "Hold" from the five ratings firms that are currently covering the firm, Marketbeat.co
Wall Street Analysts Predict a 55.93% Upside in HUTCHMED (HCM): Here's What You Should Know
10:56am, Wednesday, 07'th Jan 2026
The consensus price target hints at a 55.9% upside potential for HUTCHMED (HCM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026
09:17am, Wednesday, 07'th Jan 2026
HUTCHMED (China) Limited (NASDAQ: HCM) on Tuesday shared data from the Phase 3 registration part of the ESLIM-02 clinical trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic
— Delivers rapid, durable responses in wAIHA, the more common form of this potentially life-threatening disease —
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the Pha
— NDA supported by positive Phase II registration study data in Chinese patients; follows Breakthrough Therapy Designation granted in 2023 —
Edgewise: Maintaining Buy On Part D EDG-7500 Data And Next Q2 2026 Catalyst
02:55pm, Monday, 29'th Dec 2025
Edgewise Therapeutics, Inc. maintains a Buy rating, driven by favorable interim 12-week safety data for EDG-7500 in phase 2 CIRRUS-HCM and multiple 2026 catalysts. EDG-7500 demonstrated strong tolerab
— NDA supported by results from a Phase II registration trial in China — — Second most common form of liver cancer after hepatocellular carcinoma, with generally poorer long-term survival in co
BOULDER, Colo., Dec. 24, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), today announced positive updates from the ongoing CIRRUS-HCM, Phase 2 clinical trial of EDG-7500, a novel ora
HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors
07:00pm, Tuesday, 16'th Dec 2025
— First-in-human trial of candidate from the next-generation ATTC platform — — Simultaneous China and global clinical development strategy to expedite development process — HONG KONG and SHANG
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting
07:00pm, Wednesday, 26'th Nov 2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 27, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data fro
Brokerages Set HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Target Price at $20.88
03:29am, Tuesday, 25'th Nov 2025
HUTCHMED (China) Limited Sponsored ADR (NASDAQ: HCM - Get Free Report) has received a consensus rating of "Hold" from the five ratings firms that are covering the company, MarketBeat.com reports. One
